Patients with nonsquamous NSCLC ( stage IIIB/IV or recurrent ) and no prior systemic therapy for advanced disease were randomized to IV carboplatin ( AUC , @ mg/ml min ) and paclitaxel ( @ mg/m@ ) for up to six @-week cycles , plus either oral motesanib @ mg q.d. or placebo .